The economic burden of nosocomial infections in malignant tumor patients
10.16718/j.1009-7708.2024.06.004
- VernacularTitle:恶性肿瘤患者医院感染疾病经济负担
- Author:
Chao WU
1
;
Yi LIU
;
Yonghui SHAO
;
Xiaorong YAN
;
Rui ZHANG
Author Information
1. 雅安市人民医院医院感染管理科,四川雅安 625000
- Publication Type:Journal Article
- Keywords:
nosocomial infection;
malignant tumor;
economic burden of disease;
propensity score matching;
real-world data
- From:
Chinese Journal of Infection and Chemotherapy
2024;24(6):652-657
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the economic burden of nosocomial infections (NIs) in malignant tumor patients.Methods Clinical data of malignant tumor patients treated in a tertiary Grade A hospital from January 1,2020 to December 31,2022 were collected.Propensity score matching (PSM) and marginal analysis were used to estimate the economic burden of NIs in malignant tumor patients.Results Among 21484 malignant tumors patients,205 patients developed NIs and the infection rate was 0.95％.PSM indicated that the total medical expense was 7115755 Yuan RMB for malignant tumor patients with NIs from 2020 to 2021,among which the incremental medical expense due to NIs was 5473910 Yuan RMB,accounting for 76.93％ of the total expenses.The increment in medical expenses was mainly due to the cost of laboratory diagnosis,antibacterial drugs,imaging fee and surgical treatment.NIs extended the length of hospital stay for 20.0 days per malignant tumor patient,and the indirect economic burden was 7600 Yuan RMB.The economic loss of hospital stay due to NIs was 229760 Yuan RMB (M％=5％) in the 3-year period.The ratio of hospital profit loss due to NIs was about 3.52.Conclusions NIs in malignant tumor patients will extend the length of hospital stay,increase hospital expenses and affect the improvement of medical care quality which will cause heavy economic burden to patients,families and hospitals.Controlling the cost of antimicrobial drugs,laboratory diagnosis,imaging diagnosis and surgical treatment will be a key to reducing the total hospitalization cost of malignant tumor patients with NIs.
